- Home
- IPHA vs MPA Comparison
IPHA vs MPA Comparison
Compare IPHA & MPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- MPA
- Stock Information
- Founded
- IPHA 1999
- MPA 1992
- Country
- IPHA France
- MPA United States
- Employees
- IPHA N/A
- MPA N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- MPA Finance Companies
- Sector
- IPHA Health Care
- MPA Finance
- Exchange
- IPHA Nasdaq
- MPA Nasdaq
- Market Cap
- IPHA 160.1M
- MPA 148.2M
- IPO Year
- IPHA 2019
- MPA N/A
- Fundamental
- Price
- IPHA $2.18
- MPA $11.40
- Analyst Decision
- IPHA Hold
- MPA
- Analyst Count
- IPHA 2
- MPA 0
- Target Price
- IPHA $2.00
- MPA N/A
- AVG Volume (30 Days)
- IPHA 12.3K
- MPA 25.2K
- Earning Date
- IPHA 09-17-2025
- MPA 01-01-0001
- Dividend Yield
- IPHA N/A
- MPA 3.83%
- EPS Growth
- IPHA N/A
- MPA N/A
- EPS
- IPHA N/A
- MPA N/A
- Revenue
- IPHA $14,839,695.00
- MPA N/A
- Revenue This Year
- IPHA $50.89
- MPA N/A
- Revenue Next Year
- IPHA N/A
- MPA N/A
- P/E Ratio
- IPHA N/A
- MPA N/A
- Revenue Growth
- IPHA N/A
- MPA N/A
- 52 Week Low
- IPHA $1.29
- MPA $9.87
- 52 Week High
- IPHA $3.51
- MPA $12.21
- Technical
- Relative Strength Index (RSI)
- IPHA 60.94
- MPA 55.48
- Support Level
- IPHA $2.07
- MPA $11.31
- Resistance Level
- IPHA $2.28
- MPA $11.54
- Average True Range (ATR)
- IPHA 0.09
- MPA 0.11
- MACD
- IPHA 0.01
- MPA -0.02
- Stochastic Oscillator
- IPHA 69.70
- MPA 48.15
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About MPA Blackrock MuniYield Pennsylvania Quality Fund
Blackrock Muniyield Pennsylvania Quality Fund is a closed-end fund with an investment objective to provide shareholders with as high a level of current income exempt from U.S. federal and Pennsylvania income taxes as is consistent with its investment policies and prudent investment management. The Fund seeks to achieve its investment objective by investing, as a fundamental policy, at least 80% of an aggregate of the Fund's net assets and the proceeds of any borrowings for investment purposes, in a portfolio of municipal obligations issued by or on behalf of the State of Pennsylvania, its political subdivisions, agencies, and instrumentalities and by other qualifying issuers.